OliX Pharmaceuticals Announces IND Submission to US FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

OliX Pharmaceuticals Announces IND Submission to US FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

By, Admin 4 July 2022

OliX Pharmaceuticals, Inc. a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US. AMD is the most common cause of blindness in the industrialized world, which affects more than 170 million people worldwide. AMD presents in 2 forms, geographic atrophy (GA) and neovascular AMD. Although treatments exist for many patients with neovascular AMD, a substantial number of patients remain insufficiently treated, and there is no FDA-approved drug for GA up to date. Therefore, the development of novel and safe AMD treatments presents as an important unmet medical need that OliX addresses with the development of OLX10212 for both indications. According to GlobalData, the global market for the treatment of AMD is expected to grow from USD 11.7 billion in 2022 to USD 18.7 billion in 2028.1)

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!